Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Shares Outstanding (Diluted Average) (2020 - 2025)

KalVista Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $49.7 million for Q2 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 34.98% to $49.7 million in Q2 2025 year-over-year; TTM through Apr 2025 was $49.7 million, a 34.98% increase, with the full-year FY2025 number at $49.7 million, up 34.98% from a year prior.
  • Shares Outstanding (Diluted Average) hit $49.7 million in Q2 2025 for KalVista Pharmaceuticals, up from $46.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for KALV hit a ceiling of $49.7 million in Q2 2025 and a floor of $19.1 million in Q2 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $36.7 million across 4 years, with a median of $34.7 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): increased 7.58% in 2021 and later skyrocketed 35.09% in 2024.
  • Tracing KALV's Shares Outstanding (Diluted Average) over 4 years: stood at $19.1 million in 2021, then soared by 81.03% to $34.6 million in 2023, then skyrocketed by 35.09% to $46.7 million in 2024, then grew by 6.33% to $49.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for KALV at $49.7 million in Q2 2025, $46.7 million in Q4 2024, and $46.2 million in Q3 2024.